The sutureless method of transplantation of fibrin glue-coated, freeze-dried amniotic membrane (FCFD-AM) is both safe and straightforward.
The sutureless method of transplantation of fibrin glue-coated, freeze-dried amniotic membrane (FCFD-AM) is both safe and straightforward, according to a study published in the April issue of Investigative Ophthalmology and Visual Science.
Eiichi Sekiyama and colleagues from the Kyoto Prefectural University of Medicine and Doshisha University, Japan and Lancaster University, UK made a bioadhesive-coated, freeze-dried amniotic membrane (AM). This was achieved by freeze drying the AM in a vacuum and applying the minimum amount of fibrin glue necessary to retain adhesion on the chorionic side and by sterilizing it by radiation. The resulting AM was characterized for its biological and morphological properties by immunohistochemical and electron microscopic examination. The FCFD-AM was transplanted onto a rabbit scleral surface, without sutures, to examine its biocompatibility.
Immunohistochemistry revealed that fibrinogen existed on its chorionic side and that the process of applying fibrin glue did not affect its biological and morphologic properties. Electron microscopic examination of the chorionic side, revealed tiny microfibrils and showed that the epithelial surface of FCFD-AM consists of intact basal lamina similar to that of FD-AM.
The transplantation was straightforward and the graft adhered to the bare sclera instantly. Although the fibrinogen naturally biodegraded within two weeks, the FCFD-AM remained for at least 12 weeks after transplantation. The conjunctival epithelium on the FCFD-AM was well stratified and not keratinized, indicating that it supports normal cell differentiation.
The authors concluded that FCFD-AM could be a relatively safe and simple method of ocular reconstruction.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.